Dr. Paul Oberstein, a pancreatic cancer expert and member of the Academic GI Cancer Consortium (AGICC), discusses new data showing positive results from a Phase 3 pancreatic cancer study of an experimental drug by Revolution Medicines.

Paul Oberstein, M.D., is the director of GI Medical Oncology in the Perlmutter Comprehensive Cancer Center at NYU. Prior to his posting at NYU Langone, Dr. Oberstein was a member of the Herbert Irving Comprehensive Cancer Center at Columbia University, an assistant professor at Columbia University College of Physicians and Surgeons, and an attending physician at New York-Presbyterian/Columbia University Medical Center.